Evaluation of the effect of Shalomin on the treatment and improvement of symptoms in patients with Covid 19

Phase 3

Recruiting

• Conditions: Coronavirus disease (COVID-19).; COVID-19, virus identified; U07.1

• Registration Number: IRCT20200725048199N1
• Lead Sponsor: Dezfoul University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 146

Inclusion Criteria

Positive coronavirus test
willingness to participate in the study
not receiving any medication other than the common COVID19 treatment protocol
people who need to be hospitalized based on blood oxygen saturation and respiratory status.

Exclusion Criteria

Infection with other microbial or viral infections
severe form of COVID19 disease
inability to use syrup and respiratory spray Shalomin

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Alteration of clinical and paraclinical symptoms of Covid 19 in patients. Timepoint: Once every three days after starting treatment until finally one month after starting treatment. Method of measurement: Based on vital signs and paraclinical information.;Corona virus test result. Timepoint: Two weeks after starting treatment. Method of measurement: Based on the results of corona virus polymerase chain reaction test.